Next-generation transcatheter heart valves: current trials in Europe and the USA.
Transcatheter aortic valve implantation (TAVI) has proven to be a viable alternative for patients with symptomatic severe aortic stenosis who are at high risk for surgical aortic valve replacement. At the same time, there is increasing evidence that moderate-to-severe periprosthetic aortic regurgitation after TAVI is associated with dramatically increased mortality and morbidity. The issue of proper positioning of the valve, including the ability to reposition and recapture the device, must be dealt with before the use of TAVI can be extended to younger, healthier patients. The next generation of transcatheter heart valves will most likely address repositionability to facilitate accurate placement with additional features that minimize paravalvular leakage. Upcoming devices promise to improve outcomes and usability of current TAVI systems.
Medizinische Klinik und Poliklinik II, Universitätsklinikum Bonn, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany.
Jan-Malte
JM
Sinning
Nikos
N
Werner
Georg
G
Nickenig
Eberhard
E
Grube
D001021:Aortic Valve / Q000473:pathology / Q000601:surgery*; D000082882:Bicuspid Aortic Valve Disease; D035843:Biomedical Research / Q000639:trends*; D006328:Cardiac Catheterization / Q000379:methods*; D005060:Europe; D019317:Evidence-Based Medicine; D006330:Heart Defects, Congenital / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D006349:Heart Valve Diseases / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D019918:Heart Valve Prosthesis Implantation / Q000379:methods*; D006801:Humans; D014481:United States